The use of biologics has significantly changed the management of rheumatoid arthritis over the last decade, becoming the cornerstone treatment for many patients. The current therapeutic arsenal consists of just under 10 biologic agents, with four different mechanisms of action. Several studies have demonstrated a large interindividual pharmacokinetic variability, which translates to unpredictability in clinical response among individuals. The present review focuses on the pharmacokinetics and pharmacodynamics of biologic agents approved for rheumatoid arthritis. The literature relating to their concentration-effect relationship and the use of pharmacokinetic-pharmacodynamic modelling to optimize drug regimens is analysed. Due to the scarcity and complexity of these studies, the current dosing strategy is based on clinical indexes/aspects. In general, dose individualization for biologics should be implemented increasingly in clinical practice as there is a direct benefit for treated rheumatoid arthritis patients. Moreover, there is an indirect benefit in terms of cost-effectiveness.
Structure of biologics
Biologics are mainly monoclonal antibodies (mAbs), which can be defined as antibodies produced by a single clone of B cells [12] . Thus, their structure differs greatly from that of the traditional small drug molecules. Techniques for mAbs production have evolved considerably. For this purpose, the properties of myeloma cells have been utilized as they are monoclonal and secrete immunoglobulin. The fusion of myeloma cells with normal B cells yields hybridomas. Classically, the method for obtaining mAbs was to immunize laboratory animals with the selected hybridoma with which unlimited quantities of mAb could be produced. More recently, in order to eliminate animal-based production and to produce large amounts of therapeutic mAbs, in vitro alternatives have raised [12] .
All therapeutic mAbs are of the immunoglobulin (Ig) G isotype subclass 1, with a molecular weight of around 150 kDa. Their basic structure consists of two identical heavy chains (H) and two identical light chains (L) joined by disulfide bridges. Both the H and L chains, are made up of variable and constant domains. At the same time, the IgG structure can be divided into two identical antigen-binding portions (Fabs) and a crystallizable portion (Fc). In addition to the variable domain, there are hypervariable regions which bind to the target antigen with high affinity and specificity. The Fc domain structure confers the immune effector function of antibodies by interacting with Fcγ receptors, the neonatal Fc receptor and complement [9, [12] [13] [14] .
The first mAbs developed were murine, thus having serious limitations for clinical use due to a variable effector function, low serum half-life and the development of human antimouse antibodies. As a result of recent advances in biotechnology, the subsequent mAbs have less murine content at the expense of human content. There are currently three structural classes of mAbs: (i) chimeric (murine variable regions and human constant regions); (ii) humanized (only hypervariable regions are of murine origin); and (iii) human (without murine content). Although the humanization of antibodies is expected to decrease their immunogenicity, all classes of therapeutic mAbs can trigger antibody production in the host [9, 13] .
Biologic agents in RA
Biologics have brought about a shift in RA treatment and transformed patient outcomes [10, 11, 15] . Anti-TNF-α agents were the first to be studied and approved for RA. Currently, five TNF inhibitors are available for clinical use, with etanercept and infliximab as early examples, followed by adalimumab and, most recently, certolizumab and golimumab [5, 6] . Despite clinical trials showing similar efficacy [4] , these are not equivalent in terms of pharmacodynamics (PD) as a result of different molecular structures and signalling disruption. This may explain why patients who do not respond to a given TNF inhibitor may respond to another one [9] . Moreover, the route of administration also differs between them, implying different pharmacokinetic (PK) profiles. Besides these anti-TNF-α agents, other drugs, with different mechanisms of action, have also shown efficacy in RA. For instance, rituximab, a B cell-depleting mAb, has shown good efficacy, even though it was initially approved for haematological diseases [4, 9, 11] . Similarly, abatacept, a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-IgG fusion protein that selectively inhibits the interaction between T-and antigen-presenting cells [16] , has also been approved for RA treatment. Finally, with the finding that IL-6 is overexpressed in several inflammatory diseases, including RA, an IL-6-directed therapy, tocilizumab [4, 7] , has been the most recent to gain approval.
Limitations of biologics
It is common knowledge that no pharmacological treatment is free from potential toxicity, and this is also the case for biologic agents. Their use has led to a major concern over safety, derived from their mechanism of action. The safety of biologics has been discussed in detail elsewhere [10, 17, 18] . The inhibition or blockade of the actions of certain cytokines may interfere in important signalling pathways in the normal immune response, thus increasing the risk of infection and/or malignancy [10, 17, 19] . For example, an increased risk of serious infectious events, including tuberculosis and infections caused by opportunistic pathogens, has been reported in patients on biologics [17, 19] . As recommended in the Summary of Product Characteristics of biologic agents, prescreening for latent tuberculosis should be performed, and vigilance during and after the treatment is required. Moreover, biological therapy is strictly contraindicated in cases of severe active infection, immunocompromised patients and severe cardiac insufficiency [20] [21] [22] [23] [24] [25] [26] [27] .
Although there is growing evidence that disease remission can be achieved and maintained better in the early than the later stages of the disease, the use of biologic agents in the very early stages could be hampered mainly because of their cost [28] .
Finally, several studies claim that a considerable proportion of patients show insufficient clinical response, ranging from 20% to 40% of patients on TNF inhibitor treatment regimens [4, 29] . Loss of efficacy has been strongly related to anti-drug antibody (ADA) production and, as a consequence, to subtherapeutic serum drug concentrations. However, not all biologic drug responses have been influenced by ADAs, as some are associated with negligible levels of immunogenicity [30] . More studies are needed to find a plausible explanation for this issue.
There is therefore an obvious need to improve the risk:benefit ratio for these therapies. As safety and efficacy concerns have been, in part, related to serum drug concentrations [9, 31] , and biologics present a high PK variability, drug monitoring is proposed as a favourable tool for optimizing this ratio [31] .
Therapeutic drug monitoring (TDM)
TDM is more than simply the analysis of a drug concentration in the blood and the report of its value. It also comprises the interpretation of the measured value by means of mathematical/PK principles to draw appropriate conclusions so as to recommend the most suitable regimen to optimize treatment.
The concept of TDM suits biologic therapies as they fulfil the key criteria necessary for this process to be useful [32] , such as: (i) several PK studies demonstrate that the serum concentrations of different biologic agents overlap in individuals receiving different doses, showing a significant interindividual variability [32, 33] ; (ii) there is a good relationship between serum drug concentrations and therapeutic and/or toxic effect [9] ; (iii) they show a narrow therapeutic window in drug concentrations; and (iv) a drug assay is available.
However, there is still debate about its utility in clinical practice. One could claim that TDM is generally not needed in clinical practice as large studies have been conducted during the development phases of these drugs, and it could lead to an increase in costs. By contrast, there is a trend towards recommending and implementing dose de-escalation strategies in patients with RA who are in sustained remission or have low disease activity, to improve the risk:benefit ratio and avoid overtreatment, and this is also associated with a reduction in costs [11, 33] . Dose reduction is reported to be carried out empirically [11, 33] instead of applying TDM. This is mainly because of the lack of consistent studies that shed light on the best therapeutic target concentration, the selection of which patients are appropriate candidates for the measurement of serum drug concentrations, and the positive and negative predictive values that should be considered for the further therapeutic recommendation [31] .
However, motivated by the huge variability observed in the PK parameters of drugs in patients, population PK emerged with the clear aim of identifying and quantifying this variability (inter-and intraindividually) as well as assessing the effect of different factors (such as age, gender, concomitant pathologies or concomitant treatment) on drug PK parameters. In short, population PK can be defined as the study of the inter-and intraindividual variability of serum drug concentrations when they are given at the scheduled dosage to a large group of patients with already defined physiological and clinical characteristics [34] [35] [36] .
To quantify the importance of the relationship between a drug's PK behaviour and its effect (for example, the relationship between serum drug concentrations and disease activity), PKPD modelling was developed [37] . Recently, it has gained ground in clinical practice as a useful tool not only to establish the dosage of a new drug, but also to optimize drug dose regimens. A few population PK/PD studies have been carried out in patients with RA. Data on the population PK parameters relating to mAbs absorption, distribution, elimination and identified covariate effects from these studies are presented in Table 1 (see Appendix S1 for details).
In order to demonstrate the utility of TDM in clinical practice, Jani et al. [38] recently investigated whether the presence of ADAs and/or random drug concentrations predicted the treatment response. A cohort of 331 patients with RA treated with adalimumab or etanercept was selected. On the one hand, the presence of ADAs and low serum adalimumab concentrations at 3 months were significant predictors of a lack of response at 12 months, according to Creatinine CL (ml min [39] also found a correlation between serum drug concentrations and an improvement in the disease activity score in 28 joints (DAS28) score in RA patients treated with adalimumab and etanercept, thus indicating that drug monitoring could be useful not only for evaluating the therapeutic response of these drugs, but also for guiding dose optimization. Other objectives of the study were to evaluate the association between ADAs levels and therapeutic response, and ADAs levels and trough serum drug concentrations. These authors found an inverse correlation between ADAs levels and therapeutic response or drug concentrations in adalimumab-treated patients. It is important to mention that the determination of ADAs may be confounded by the circulating drug concentrations as current assays measure serum concentrations of free ADA but lack sensitivity for the complex drug-antidrug antibody.
As the clinical response in patients on biologic treatments can be influenced by their PK and immunogenicity, Mazilu et al. carried out a study in which 154 patients with established RA receiving a biologic agent were recruited [40] . Their results showed that drug concentrations in patients who experienced an inadequate response while being on long-term treatment correlated with their clinical response at follow-up. Therefore, the authors supported the concept of serum drug monitoring in clinical practice. Moreover, immunogenicity assessment also seems to be helpful for optimizing and personalizing the use of these therapies as all patients receiving anti-infliximab antibodies had no EULAR response at follow-up.
TDM studies based on a single biologic agent for RA treatment are summarized below (see Appendix S1 for details).
Etanercept
Several dose comparison studies have been conducted in order to assess their safety and efficacy. For example, the PRESERVE trial [41] studied whether low disease activity would be sustained with reduced doses (25 mg weekly) or withdrawal of etanercept in patients with moderately active disease. They found that a similar percentage of patients maintained low activity disease at week 88 if treated with conventional or reduced doses of etanercept combined with MTX. Moreover, Johnsen et al. [42] demonstrated no statistically significant differences in the American College of Rheumatology (ACR) 20/50/70 response rate when the standard regimen was intensified. The link between the cumulative area under the curve (AUC) of drug concentrations over time with the ACR20 response in RA patients receiving etanercept was firstly described by Lee et al. [43] . Subsequently, Hsu et al. [44] developed a population PK/PD model to explore the feasibility of alternative dosing regimens in order to reduce potentially side effects and costs. They found a relationship between the cumulative AUC of etanercept and the ACR20/50/70 response rate and DAS28 score. They finally proposed several alternative dosing regimens with equivalent efficacy to current recommended dosage, some of which had a more convenient dosing schedule for patients. Other authors [45] suggested that therapeutic drug monitoring could be useful for adjusting dosing regimens in selected groups of patients, as they found that serum etanercept concentrations were significantly higher after 6 months of therapy in good responders compared with moderate responders and EULAR nonresponders. Chen et al. [39] found that the optimal cut-off trough levels for etanercept were 1.242 μg ml -1 and 0.800 μg ml -1 for a good EULAR response, assessed at the 6th and 12th month, respectively. These results were corroborated by Sanmartí et al. [46] , who also set the cut-off value at 1.56 μg ml -1 .
Finally, Zhou et al. [47] evaluated the impact of MTX coadministration on the PK of etanercept in patients with RA, concluding that it had no effect, so dose adjustment was not required with concurrent use of this drug.
Infliximab
In 2002, after a multicentre, randomized, double-blind, placebo-controlled trial, St Clair et al. [48] hypothesized that there could be an inadequate response to treatment with infliximab due to an incomplete suppression of TNF activity.
To test this hypothesis, they analysed the relationship between serum infliximab concentrations and treatment outcomes in 428 subjects. Up to 30% of the patients receiving 3 mg kg -1 every 8 weeks had undetectable trough serum infliximab concentrations before each infusion from weeks 22 to 54. They also found that a better outcome, reflected not only in a reduction in serum C-reactive protein (CRP) levels, but also in less progression of radiographic joint damage, was related to higher trough serum concentrations of the drug, supporting a dose-response relationship. They also used a PK model to find the most appropriate dosing schedule for achieving a sustained clinical response. They predicted that shortening the dosing interval to 6 weeks would yield higher trough serum concentrations than keeping the interdose interval to 8 weeks and increasing the dose by 100 mg. Another study, conducted by Barlow et al. [49] , involving a mixed cohort of patients with Crohn's disease and RA, assessed the clinical utility of measuring the presence of ADAs as an adjunct to trough serum infliximab concentrations. The reported median trough concentration of infliximab was 3.7 μg ml -1 but a considerable percentage of samples (23%) had a concentration ≤1 μg ml -1 . Serum infliximab concentrations were significantly lower in the positive ADA group. Among samples with an infliximab concentration ≤1.0 μg ml -1 , 85% had positive anti-infliximab antibodies compared with 37% of those with an infliximab concentration >1.0 μg ml -1 .
Variability in trough serum infliximab concentrations has been reported [50] . Therefore, in order to quantify the effect of this variability, authors such as Ternant et al. [51] developed the first population PK model. They suggested that there is need to individualize infliximab dose, taking into account the influence of MTX cotreatment and inflammation (measured using the CRP concentration) on drug clearance (CL), decreasing and increasing it, respectively.
Adalimumab
Several studies [52] [53] [54] carried out in RA patients claimed that adalimumab concentrations were related to treatment response. In fact, it was found that antibodies produced against adalimumab led to lower drug serum concentrations, which in turn resulted in a poor response. Subsequently, Ternant et al. [55] described the relationship between adalimumab concentration and effect in a post hoc analysis in 30 patients with active RA. Patients received 40 mg subcutaneous adalimumab every other week combined with MTX. Efficacy was assessed through the measurement of the DAS28 score. CRP was also considered a key variable for evaluation as its normalization has been associated with a sustained clinical response. The authors showed that this dose regimen resulted in a long delay in reaching steady-state concentrations and maximal effect. Using PKPD modelling, they concluded that this problem could easily be solved by administering a loading dose of 160 mg, as used in other diseases, such as Crohn's disease. A larger study, where 221 RA patients were also treated with 40 mg subcutaneous adalimumab on alternate weeks, established the concentration-effect curve in order to optimize treatment and reduce costs [56] . These authors identified that the therapeutic range was 5-8 μg ml -1 for maximal clinical effect, and that MTX was an important factor influencing the PK of adalimumab as patients taking MTX concomitantly had higher median adalimumab concentrations than those on adalimumab monotherapy (7.4 μg ml -1 vs. 4.1 μg ml -1 ). Chen et al. [57] recently evaluated the impact of halving the dose of adalimumab on the therapeutic response and drug concentrations. Their results showed that an adalimumab concentration above the cut-off value of 6.4 μg ml -1 might predict persistent remission after halving the dose with high sensitivity and specificity, and also prevent overtreatment with TNF antagonists. However, the cut-off value for the adalimumab concentration is a major concern as other authors have found significantly lower values [39, 46] .
Certolizumab
A Markov mixed-effect model was developed by Lacroix et al. [58] to characterize the temporal course of the ACR 20/50/70 assessments in RA patients treated with certolizumab. The model found a directly proportional relationship between individual and average drug concentrations over the last dosing interval and the probability of attaining a higher level of ACR response. The majority of the clinical effect was achieved with a maintenance dose of 200 mg every 2 weeks.
Golimumab
Hu et al. [59] built an exposure-response model of golimumab based on a population approach in RA patients, using the ACR index of improvement as a measure of change in disease activity. Data were collected from 302 patients in a phase III trial who received golimumab or placebo plus MTX every 4 weeks. None of the different variables evaluated, such as demographic variables, disease duration, creatinine CL, the presence of comorbidities, use of concomitant drugs, alcohol use and smoking status, resulted in an improvement of the model fits. Other authors studied the relationship between trough golimumab concentrations, ADAs and clinical response in RA patients treated in daily clinical practice [60] . In this case, clinical response was defined as a DAS28 value <3.2 and fewer patients were included (n = 37 and CRP concentrations were significantly inversely associated with trough serum drug concentrations over time. Therefore, patients with higher levels of inflammatory biomarkers had significantly lower serum drug concentrations. Only three patients had ADAs and all of them discontinued treatment owing to inefficacy.
Rituximab
Ng et al. [61] conducted the first population PK study with rituximab in RA. They recruited data from a single phase II study, including a total of 102 patients. Participants received either rituximab alone or in combination with cyclophosphamide or MTX because of prior failure of DMARD therapy or an inadequate response to MTX. A two-compartment linear PK model best fitted the data. The most significant covariates to explain interindividual variability were body surface area (BSA) and gender. The covariate effect of BSA in the final model explained about 32% of the interindividual variance in CL, and gender explained about the 42% of the interindividual variance in the volume of distribution of the central compartment (Vc). From these data, they concluded that although BSA influences rituximab CL and AUC, the relationship is too weak to recommend BSA-adjusted dosing. Although this effect may be measurable, it is not highly contributory.
Abatacept
Roy et al. [62] conducted a modelling and simulation study in RA patients treated with abatacept. They aimed to quantify the effect of body weight on drug exposure and to characterize the relationship between exposure and serum IL-6 concentrations. Two models were developed: (i) abatacept exposure, with a two-compartment PK model; and (ii) exposure-IL-6 response, with an indirect-response PD model. Results from the first model demonstrated that the only clinically relevant covariate was the effect of body weight on CL. The second model supported the recommended dosage of 10 mg kg -1 , as increasing the dose did not seem to result in additional clinical benefit.
Tocilizumab
Levi et al. [8] developed a population PKPD model to investigate the relationship between tocilizumab exposure and efficacy based on a previous PK model [7] . Data from 2243 patients who completed four phase III studies were included. Clinical variables were DAS28 and ACR scores, and PD biomarkers were CRP, ESR, serum amyloid A, serum IL-6 and serum soluble IL-6 receptor levels. Patients were divided into three categories, according to their estimated drug exposure cumulative area under the curve (cAUC) over the 24 weeks of the study: cAUC <100 mg*h l -1 ; cAUC:
100-200 mg*h l -1 ; cAUC >200 mg*h l -1 . PK and PD data were compared graphically within the three groups. Using the DAS28 score as the principal clinical endpoint and patients from two of the initial studies, a PKPD model was developed. The model successfully described the relationship between the DAS28 score and serum drug concentration. The authors estimated the typical tocilizumab concentration at which 50% of the maximum inhibitory effect (EC 50 ) was reached as 3.7 mg l -1 (with a large variability of 170%). The maximum inhibitory effect (E max ) of tocilizumab on the DAS28 score was estimated to be 73%, assuming a typical initial DAS28 baseline score of 6.8 (indicative of high disease activity). The authors concluded that a dose of 8 mg kg 
Discussion
Several studies have demonstrated the existing variability in serum drug concentrations within patients treated with biologic agents. Moreover, some of them have confirmed a relationship between serum drug concentrations or exposure and therapeutic response, hypothesizing the utility of TDM in clinical practice in order to optimize dosing regimens. Therefore, the use of a 'one dose fits all' approach in rheumatology, mainly proposed by pharmaceutical companies, needs to be reassessed. Recently, active dose reduction strategies in RA patients doing well on a biologic agent have been fostered by clinical guidelines [33] and recommended not only to avoid dosedependent adverse effects, but also to achieve costeffectiveness [31] . However, due to the reduced number of PKPD studies involving dosage optimization of biologic agents, physicians have been forced to do this empirically, considering only clinical indices as a reference tool for treatment response. A shift in daily practice for TDM should be encouraged, and population PKPD models could play an important role as a support tool for further dosage optimization.
Different variables have been tested in population PKPD studies in order to determine their influence on drug PK behaviour and the variability in serum drug concentrations. In general, CL was the most affected PK parameter, mainly by age and weight/gender. This is the case with etanercept, adalimumab and rituximab [55, 61, 63, 64] . Abatacept CL was also affected by body weight [62] and tocilizumab CL by gender, BSA, and levels of high-density lipoproteincholesterol and rheumatoid factor [7] . Moreover, cotreatment with MTX may also influence infliximab CL. In reference to other PK parameters, it has been found that the central volume of etanercept, infliximab, golimumab, and tocilizumab central volume is affected by race, weight, total protein and albumin, respectively [7, 51, 63, 65] . There is also evidence to suggest that immunosuppressive agents have an impact on mAb PK. This is the case in the coadministration of MTX with infliximab [51] and adalimumab [56] . Although an apparent decrease in mAb CL was noted in these studies, the precise mechanism could not be elucidated. A possible explanation could be a reduction in immunogenicity, and therefore a lower rate of ADA development and/or an alteration in the target expression or cell number [66] .
The development of ADAs has also been a topic of study in RA patients treated with biologics. A relationship between the presence of ADAs and lower serum drug concentrations has been demonstrated particularly for adalimumab and infliximab, affecting treatment efficacy [30] . However, it should be noted that comparison between different studies on mAbs is difficult to perform owing to limitations in current available bioanalytical methods.
Ideally, the optimal scheme should be found for each patient. TDM can help to achieve this aim as it has shown its benefits in terms of reducing mortality and morbidity, and increasing medication safety [67] . The new concept of using TDM to improve not only safety, but also outcomes is being implemented increasingly. In the case of intravenous agents, individual adjustments of dose could easily be performed. By contrast, we face a big challenge with subcutaneous agents as they are mostly produced commercially in fixed doses, so individualizing dosage could be problematic. Nevertheless, there is a trend towards the subcutaneous route of administration (compared to the iv) not only because they seem to be more convenient for patients, but also for healthcare structures. Therefore, further research on the development of subcutaneous biologic agents is needed to improve the treatment of patients. Finally, it should be borne in mind that it is essential to conduct prospective clinical trials for each biologic agent and each indication, to establish the exposure-response relationship which would subsequently enable pharmacological treatment to be individualized.
Conclusion
Currently, RA treatment includes several therapeutic strategies based on biologic agents. As their usage is spreading, the study of factors and covariates that could have a relevant influence on serum drug concentrations and exposure would be extremely useful to better understand and predict in advance the PK/PD behaviour of drugs. Moreover, the application of population PK/PD models in the clinical setting would enable the selection of suitable doses for specific patients at the same time a cost-efficient approach is being considered.
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